New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 24, 2012
10:25 EDTAGN, VPHM, TWX, RBCN, STR, PVH, LAMR, CTB, BODY, RHIOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Allergan (AGN) upgraded to Outperform from Underperform at CLSA... Body Central (BODY) upgraded to Outperform from Perform at Oppenheimer... Cooper Tire (CTB) upgraded to Buy from Hold at Deutsche Bank... Lamar Advertising (LAMR) upgraded to Outperform from Market Perform at Wells Fargo... PVH Corp. (PVH) upgraded to Overweight from Neutral at Piper Jaffray... Questar (STR) upgraded to Buy from Neutral at UBS... Rubicon (RBCN) upgraded to Neutral from Sell at Goldman... Time Warner (TWX) upgraded to Overweight from Equal Weight at Morgan Stanley... ViroPharma (VPHM) upgraded to Outperform from Market Perform at Wells Fargo... Robert Half (RHI) upgraded to Buy from Neutral at BofA/Merrill.
News For AGN;BODY;CTB;LAMR;PVH;STR;RBCN;TWX;VPHM;RHI From The Last 14 Days
Check below for free stories on AGN;BODY;CTB;LAMR;PVH;STR;RBCN;TWX;VPHM;RHI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 16, 2014
05:37 EDTAGNValeant, Pershing Square, Allergan settle pending litigation before DE Court
Subscribe for More Information
September 15, 2014
11:57 EDTAGNPershing Square submits additional meeting requests
Pershing Square Capital Management announced that on Friday it submitted to Allergan (AGN) additional special meeting requests from shareholders owning approximately 0.6% of Allerganís shares. With these requests, Pershing Square has delivered requests from 51 institutions representing 35.68% of the outstanding common stock of Allergan. At the special meeting, Allergan shareholders will have the opportunity to voice their support for a number of matters, including the removal of six incumbent members of the Allergan board, the appointment of an independent slate of directors, amendments to Allerganís bylaws to eliminate onerous restrictions on the calling of a special meeting, a request that Allergan engage in negotiations with Valeant Pharmaceuticals(VRX) and Pershing Square, and certain other actions to improve corporate governance of Allergan.
07:29 EDTTWXSony's 'No Good Deed' tops weekend box office, WSJ reports
Subscribe for More Information
September 12, 2014
10:00 EDTPVHOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:02 EDTAGNPershing submits special meeting requests totaling 35% of Allergan shares
Subscribe for More Information
06:32 EDTPVHPVH Corp. initiated with a Buy at Wunderlich
Subscribe for More Information
05:09 EDTAGNAllergan comments on Pershing Square delivery of additional requests
Allergan (AGN) commented on Pershing Square Capital Management delivery of additional requests from stockholders owning 1.5% of Allerganís shares to call a Special Meeting of Stockholders. Allergan will review these requests in addition to the requests from stockholders owning 2.8% of Allerganís shares that were delivered on September 3. The company issued the following statement: Notwithstanding Pershing Square and Valeant Pharmaceuticals (VRX) efforts to change the subject, Allergan recognizes that what actually matters is value, and thatís what the company is focusing on delivering to stockholders. In that regard, Allerganís current strategic plan is expected to deliver a compounded annual growth rate of greater than 20% EPS growth, including estimated 2016 EPS at approximately $10.00. Allergan has already scheduled the Special Meeting for December 18. As such, the delivery of additional requests for the Special Meeting by Pershing Square is not a meaningful development. The lawsuit in California is seeking an order barring Valeant, Pershing Square, Ackman, and entities affiliated with them from voting shares that Allergan believes were acquired in violation of the federal securities laws, including insider trading. If Allerganís motion for a preliminary injunction is granted, it would prevent Valeant, Pershing Square, and Ackman from voting their shares at any meeting of stockholders.
September 11, 2014
11:10 EDTTWXFox COO Carey says company has 'moved on' from Time Warner, THR reports
Subscribe for More Information
11:08 EDTAGNAllergan shareholders owning 35% to ask for meeting, Reuters says
Subscribe for More Information
09:52 EDTAGNValeant to submit consent from 35% of Allergan holders, CNBC reports
Subscribe for More Information
06:17 EDTTWXTime Warner not planning HBO IPO, comments on Fox, NY Post reports
Time Warner (TWX) CEO Jeff Bewkes told the Goldman Sachs Communacopia conference that the company is not planning an IPO or tracking stock for HBO, the New York Post reports. Bewkes also commented that the company took 21st Century Fox's (FOXA) takeover offer "very seriously," but it was determined that the integration process would be such a "large undertaking" that shareholders of both companies "would be exposed to incredible and unnecessary risks." Reference Link
September 10, 2014
11:22 EDTPVHOptions with decreasing implied volatility
Subscribe for More Information
07:31 EDTTWXGoldman to hold a conference
Subscribe for More Information
07:05 EDTPVHPVH Corp.removed from U.S. Focus List at Credit Suisse
September 9, 2014
16:04 EDTAGNPershing Square reports 9.7% stake in Allergan, sends letter to board
Pershing Square Capital Management sent a letter to the board of Allergan that highlights several reasons why Allergan is extremely shareholder unfriendly and why now is the time for Allergan's management team to wake up. In the letter, Pershing Square said: "Since the bid was announced in April, 75% of Allerganís shareholders have sold all or a portion of their investment including the companyís largest shareholder, which has sold its entire position. These shareholders are sending the board a message. They would not have sold if they believed that Allergan stock was worth more than current values... We note CFO Jeff Edwards recent decision to retire from the company at age 53 for family reasons, and his replacement by an investor relations executive rather than an experienced public company CFO. The notion that Allergan should execute the largest acquisition in its history led by an investor relations executive is a frightening proposition. While we respect an executiveís need to retire from a company for family reasons, Edwards exit also calls into question the companyís forward earnings guidance which shareholders expected him to execute on when the Company presented these projections on July 21st. I had expected that at some point one or more directors would have woken up and smelled the coffee. There is still time for a subset of directors to rescue their reputations by taking over leadership of this process from David Pyott and his handpicked advisors and doing what you are paid $400,000 per year to do on behalf of the companyís owners."
12:02 EDTPVHOptions with decreasing implied volatility
Options with decreasing implied volatility: KERX CIEN FNSR PAY BKS PVH NAV BYI FTR JOY
07:28 EDTTWXFOX pursues reality TV joint venture agreement, Hollywood Reporter says
21st Century Fox (FOX, FOXA) president and COO Chase Carey said that the company doesn't want to pursue Time Warner (TWX) again or look for another large deal, but the firm is aiming to finalize an agreement to create a reality television joint venture agreement comprised of Shine Group, Endemol and Core Media in the future, according to Hollywood Reporter, citing comments from Carey. Reference Link
06:42 EDTAGNLew expects to make decision on combating inversion deals soon, NY Times reports
Subscribe for More Information
September 8, 2014
10:42 EDTPVHOptions with decreasing implied volatility
Options with decreasing implied volatility: KERX CONN CIEN INSM FNSR PAY PVH SWY
07:21 EDTAGNJazz looks more attractive for Allergan than Salix, says Wells Fargo
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use